mouse oscc cell line moc2  (Absolute Biotech Inc)

Journal: Theranostics

Article Title: Tumor immunomodulation by nanoparticle and focused ultrasound alters gut microbiome in a sexually dimorphic manner

doi: 10.7150/thno.99664

Figure Lengend Snippet: MOC2 tumor growth pattern showed sex-based difference and shift in microbial abundance. A) Line graphs depicting differential MOC2 tumor growth rates in male and female mice (n=6, ****p<0.0001, Two-way ANOVA with Tukey's multiple comparison); B) Representative images of healthy and tumor bearing female and male mice. C) Microbiome alpha diversity calculated using Simpson index (n=5); D) Principal coordinate analysis of Bray-Curtis distances shows significant separation between groups (PERMANOVA test values). Each point represents an individual's gut microbiota based on 16S sequencing; E) Bar plot of the relative genus-level abundance in healthy and tumor-bearing male and female mice; F) Differential abundance analysis of the microbiome between healthy and tumor-bearing male and female mice using edgeR (species with p < 0.05 shown, * significance at FDR < 0.05; tumor-bearing mice as baseline); G) C lustered heatmap of the top 40 genera for four groups of mice, with female and male (healthy and tumor-bearing) forming distinct clusters.

Article Snippet: Mouse OSCC (MOC2) cell line (cat#EWL002-FP) was purchased from Kerafast, Boston, MA, USA.

Techniques: Comparison, Sequencing

Journal: Theranostics

Article Title: Tumor immunomodulation by nanoparticle and focused ultrasound alters gut microbiome in a sexually dimorphic manner

doi: 10.7150/thno.99664

Figure Lengend Snippet: CRT-NP & HT immunotherapies showed superior therapeutic response in female mice compared to male. A) C57BL6 mice bearing unilateral flank tumors were treated seven days post-inoculation (n=6). Three intratumoral injections of CRT-NP at 20 µg CRT plasmid was performed. The HT group received two treatments covering 10-20% of the total tumor volume. Fecal samples were collected from all mice before inoculation and at the time of mice sacrifice (20 days post inoculation). B&C) , Line graphs representing MOC2 tumor growth post CRT-NP & HT treatments in female (B) and male (C). D) Median tumor regression percentage with CRT-NP & HT treatments in female and male mice compared to untreated control at the day of mice sacrifice (D20 post-inoculation). E) Tumors weights at the completion of study endpoint. Two-way ANOVA test was used to analyze tumor growth in line graph and one-way ANOVA was used for bar graphs analysis, * p<0.05, *** p<0.0005, **** p<0.0001.

Article Snippet: Mouse OSCC (MOC2) cell line (cat#EWL002-FP) was purchased from Kerafast, Boston, MA, USA.

Techniques: Plasmid Preparation, Control

Journal: Theranostics

Article Title: Tumor immunomodulation by nanoparticle and focused ultrasound alters gut microbiome in a sexually dimorphic manner

doi: 10.7150/thno.99664

Figure Lengend Snippet: CRT-NP & HT therapies efficacy is driven by distinct set of immune cells. A) Flow cytometry analysis and gating strategy utilized to estimate distinct CD45+ immune cell number infiltrating MOC2 TME. B) Bar graph representing cell counts of CD8- CD4+ T helper cells, CD8+ CD4- cytotoxic T cells, and IFNγ and GranzymeB expressing CD8+ cytotoxic T cells, in TME of untreated, CRT-NP & HT treated tumors. C) Bar graph representing cell counts of CD11b+ CD11c- macrophages, MHC-II+ CD86+ M1 macrophages, Ly6Chi LY6G- M-MDSCs, in TME of untreated, CRT-NP & HT treated tumors of male and female mice. D) Bar graph representing CD3- Natural Killer cell counts, NK1.1+ CD3- NK cells, NK1.1+ GranzymeB+ cytotoxic NK cells, NK1.1+ IFNγ+ activated NK cells, in TME of untreated, CRT-NP & HT treated tumors of male and female mice. E) Pearson R correlation plot representing interaction profile of various TME associated immune cells, serum cytokines and chemokines levels and tumor volume. Immune cell counts are normalized and represented as cell number per mg of tumor. Difference among treatment groups (n=6) were analyzed using One-way ANOVA with Fisher test, * p<0.05, ** p<0.005, *** p<0.0005. P values for Pearson R correlation analysis is provided in Table . MQ: Macrophages, Activated M1: MHC-II+ CD86+ macrophages, Activated DC: MHC-II+ CD86+ dendritic cells (CD11c+ CD11b-).

Article Snippet: Mouse OSCC (MOC2) cell line (cat#EWL002-FP) was purchased from Kerafast, Boston, MA, USA.

Techniques: Flow Cytometry, Expressing

Journal: Frontiers in Immunology

Article Title: Adrenergic receptor signaling regulates the CD40-receptor mediated anti-tumor immunity

doi: 10.3389/fimmu.2023.1141712

Figure Lengend Snippet: A schematic representation of the in-vitro BMDC isolation and treatment plan is shown. Bone marrow cells derived from C57BL/6 female mice were cultured in DC conditioning media and the expression of CD11c was confirmed after 5 days of culture. BMDCs with ≥80% CD11c expression were categorized as naïve (nDCs) or induced DCs (iDCs) based on exposure to MOC2 tumor cell lysate. The cells were then treated with 1 μM ISO (a β2AR agonist) and 10 μg/ml αCD40 (a CD40 agonist) for 48 hours before analysis. Schematic created with BioRender.com .

Article Snippet: Mouse OSCC (MOC2) cell line (EWL002-FP) was purchased from Kerafast, Boston, MA, USA.

Techniques: In Vitro, Isolation, Derivative Assay, Cell Culture, Expressing

Journal: Frontiers in Immunology

Article Title: Adrenergic receptor signaling regulates the CD40-receptor mediated anti-tumor immunity

doi: 10.3389/fimmu.2023.1141712

Figure Lengend Snippet: Treatment design of the murine efficacy and immune-evaluation study. (A) Propranolol (10mg/kg of BW) was administered subcutaneously daily 5 days post-inoculation. Two 30 µg αCD40 intratumoral injections were administered at 8 days intervals in the tumor (~50 mm 3 volume). Mean tumor volume and anti-tumor immune cells were compared on day 28 post-inoculation (Timeline created with BioRender.com). (B) The combination of Prop+αCD40 demonstrated a significant reduction in tumor volume compared to the control on day 28 post-inoculation, while monotherapies did not show any significant differences. These results suggest that the combination therapy of Prop+αCD40 is more effective in reducing tumor growth compared to either Prop or αCD40 alone. Immune cells infiltrating MOC2 tumors (n=5 mice/group) analyzed by flow cytometry showed superior immunomodulation with Prop+αCD40. (C) Frequencies of CD3+ T-cells, especially CD8+ T-cells infiltrating tumors were enhanced at the highest level by combination treatment vs untreated control and monotherapies. The ratio of cytotoxic T-cells (CD8+ GZMB+) to T regulatory cells (CD4+ Foxp3+) was increased significantly in αCD40 treated groups relative to the control. (D) CD11c+, MHC-II+ CD86+ double positive (gated at CD45+ CD11c+) & MHC-II+ CD40+ double positive (gated at CD45+ CD11c+) dendritic cell frequencies showed significant enhancements in the presence of Prop and αCD40. Statistical analysis was carried out using One-way ANOVA & Two-way ANOVA multiple comparison tests. P values less than 0.05 were considered significant. * P < 0.05, ** P < 0.005, *** P < 0.0005, **** P < 0.0001. ns, nonsignificant.

Article Snippet: Mouse OSCC (MOC2) cell line (EWL002-FP) was purchased from Kerafast, Boston, MA, USA.

Techniques: Flow Cytometry